- Home
- ELE vs PVLA Comparison
ELE vs PVLA Comparison
Compare ELE & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$122.94
Company Overview
Basic Information| Metric | ELE | PVLA |
|---|---|---|
| Founded | N/A | 2015 |
| Country | Canada | United States |
| Employees | 13 | 14 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ELE | PVLA |
|---|---|---|
| Price | $18.16 | $122.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 15 |
| Target Price | $32.50 | ★ $171.87 |
| AVG Volume (30 Days) | ★ 210.2K | 205.7K |
| Earning Date | 03-24-2026 | 05-14-2026 |
| Dividend Yield | ★ 0.17% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $109.25 | N/A |
| Revenue Next Year | $16.14 | $104,350.18 |
| P/E Ratio | $255.64 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.01 | $20.20 |
| 52 Week High | $26.96 | $151.18 |
Technical Indicators
Market Signals| Indicator | ELE | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 44.14 | 49.67 |
| Support Level | $16.13 | $108.99 |
| Resistance Level | $20.73 | $133.53 |
| Average True Range (ATR) | 0.89 | 6.87 |
| MACD | -0.09 | -0.41 |
| Stochastic Oscillator | 21.55 | 42.79 |
Price Performance
Historical Comparison ELE
PVLA
About ELE Elemental Royalty Corporation
Elemental Royalty Corp is engaged in exploration discovery, royalty generation, royalty acquisition, and strategic investments.
About PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.